NASDAQ:CTMX - CytomX Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.82 -0.16 (-0.94 %)
(As of 01/16/2019 02:07 PM ET)
Previous Close$16.98
Today's Range$16.74 - $17.75
52-Week Range$12.51 - $35.00
Volume9,995 shs
Average Volume393,199 shs
Market Capitalization$750.72 million
P/E Ratio-14.88
Dividend YieldN/A
Beta0.85
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185

Debt

Current Ratio5.48
Quick Ratio5.48

Price-To-Earnings

Sales & Book Value

Annual Sales$71.62 million
Price / Sales10.57
Price / Cash FlowN/A
Book Value$1.82 per share
Price / Book9.24

Profitability

Net Income$-43,090,000.00
Net Margins-68.90%
Return on Assets-12.67%

Miscellaneous

Employees93
Market Cap$750.72 million
OptionableOptionable

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) issued its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.11. The biotechnology company had revenue of $12.51 million for the quarter, compared to analyst estimates of $16.42 million. CytomX Therapeutics had a negative return on equity of 65.03% and a negative net margin of 68.90%. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

8 brokers have issued 1 year price targets for CytomX Therapeutics' stock. Their forecasts range from $13.24 to $40.00. On average, they expect CytomX Therapeutics' stock price to reach $32.0343 in the next year. This suggests a possible upside of 88.2% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.

What is the consensus analysts' recommendation for CytomX Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (1/8/2019)
  • 2. HC Wainwright analysts commented, "We have valued CytomX Therapeutics based on a discounted cash flow (DCF) assessment that is driven by a combination of CX-072 future sales and BMS-986249 future royalties on net sales." (9/13/2018)

Has CytomX Therapeutics been receiving favorable news coverage?

Media coverage about CTMX stock has trended positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the stock's share price in the next several days.

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
  • Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 40)
  • Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)
  • Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
  • Ms. Danielle Olander, Sr. VP of Talent & Admin. Operations

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $17.02.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $750.72 million and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is http://www.cytomx.com.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  407
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel